C

Cara Therapeutics
D

CARA

4.63000
USD
-0.07
(-1.49%)
مغلق
حجم التداول
3,209
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
21,165,082
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACB
    -0.04000
    (-1.03%)
    3.86000 USD
    C
    CGC
    0.00000
    (0.00%)
    2.22500 USD
    C
    CRBP
    -0.620
    (-5.18%)
    11.350 USD
    C
    CRON
    -0.02000
    (-1.03%)
    1.92000 USD
    T
    TLRY
    -0.04000
    (-3.40%)
    1.13500 USD
    المزيد
الأخبار
المقالات

العنوان: Cara Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.